Eye on Ocular Health

ReachMD

0,0 (0)
CIÊNCIA

Eye on Ocular Health features expert commentary on the management and prevention of debilitating eye problems, such as age-related macular degeneration, diabetic retinopathy, ocular traumas, and chronic dry eye. This series features commentary from renowned ophthalmologists discussing the most successful diagnostic and treatment options emerging in practice.

30 DE ABR.

Making the Case for Dual Ang-2/VEGF-A Inhibition: Anatomical Benefits

Host: Jennifer I. Lim, MD, FARVO Guest: Carl Regillo, MD What evidence do we have that blocking Ang-2 and VEGF-A is beneficial for patients? Tune in to hear Dr. Jennifer Lim and Dr. Carl Regillo examine the anatomical and biomarker evidence surrounding dual inhibition of Ang-2 and VEGF-A. Find out how bispecific targeting can benefit patients with neovascular age-related macular degeneration and diabetic macular edema.
15 DE ABR.

Making the Case for Dual Ang-2 VEGF-A Inhibition: Durability and Drying

Host: Carl Regillo, MD Guest: Jennifer I. Lim, MD, FARVO What are the biomarkers that indicate dual targeting helps to reduce vascular leakage and suppress neovascularization? Join Dr. Carl Regillo and Dr. Jennifer Lim as they discuss the biomarkers of Ang-2 and VEGF-A suppression. Hear how to achieve earlier and faster fluid resolution in both neovascular age-related macular degeneration and diabetic macular edema.
31/10/2023

A Vision for Change: Exploring Biosimilars in Retinal Disease Management

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: Arghavan Almony, MD The production of biosimilar therapies is setting the stage for a shift in how we approach treating patients with wet AMD, diabetic retinopathy, macular edema, and other retinal diseases, but many questions remain regarding how their efficacy and safety compare to the reference products and how we can best talk to our patients about these treatment options. To help shed light on these and other FAQs, Dr. Mary Katherine Cheeley speaks with Dr. Arghavan Almony, Adjunct Assistant Professor at Wallace School of Osteopathic Medicine at Campbell University in North Carolina.
24/05/2018

Ocular Manifestations of Rheumatological Conditions

Host: Jennifer Caudle, DO Guest: Anne Negrin, MD Since eye issues are becoming increasingly common in patients with rheumatological conditions, it’s now more vital than ever that physicians are aware of their common symptoms. Joining Dr. Jennifer Caudle is Dr. Anne Negrin, an ophthalmologist in New York, to break down these symptoms and to focus on rheumatological concerns that ophthalmologists see in practice.
23/04/2018

FDA-Approved Gene Therapy Reverses Blindness in Children & Adults

Host: Jennifer Caudle, DO Guest: Jean Bennett, MD, PhD Guest: Albert Maguire, MD Power couple Drs. Jean Bennett and Albert Maguire discuss how their new therapy for the RPE65 gene, which causes retinal blindness, was recently approved by the FDA to become the first gene therapy treatment for a genetic disease in the United States and the first worldwide treatment for inherited blindness. Not only do they delve into the mechanics of the corrected gene injection, but they also explain what this milestone means for patient eligibility and how their marriage has played a role in the success of their research partnership. Dr. Jean Bennett is the F.M. Kirby Professor of Ophthalmology at the Perelman School of Medicine at the University of Pennsylvania, and Dr. Albert Maguire is a Professor of Ophthalmology at the Hospital of the University of Pennsylvania and Attending Physician in the Division of Pediatric Ophthalmology at Children’s Hospital of Philadelphia.
25/11/2015

Injectable Medication as an Alternative Treatment for Diabetic Eye Disease

[Read the Article] Proliferative diabetic retinopathy (PDR) is a leading cause of vision loss in patients with diabetes, resulting in up to 24,000 cases of blindness each year in the United States. Laser therapy has been the most common treatment used to help reduce severe vision loss, but the procedure has many side effects including permanent loss of peripheral vision and swelling of the retina. A group of researchers from across the US tested an alternative treatment using an injectable medication called ranibizumab, to see if it would be as effective as the laser therapy. They studied more than 300 patients with PDR, assigning them to either receive standard laser therapy or an injection into the eye. In total, they treated close to 400 eyes. Outcomes, especially loss of vision, were compared at two years. Over the two year period, researchers found that patients receiving the injections of medication had fewer side effects and did somewhat better in terms of vision loss than those who received laser therapy. [Watch more videos of The JAMA Report]
19/10/2015

Keeping a Clinical Eye on Sickle Cell Retinopathy

Host: Jennifer Caudle, DO Dr. Jennifer Caudle welcomes Dr. Patrick Spencer, Chairman of the Department of Ophthalmology at Grandview Medical Center in Dayton, Ohio. Their discussion centers on primary care manifestations of sickle cell retinopathy, from early to late-stage presentations and the gold standard treatment approaches along this disease course.
03/08/2015

Uncommon Details on Common Ocular Conditions

Host: Brian P. McDonough, MD, FAAFP Dr. Brian McDonough welcomes Dr. Gail L. Torkildsen, staff ophthalmologist at Andover Eye Associates and one of the leading Dry Eye Principal Investigators in the world. Dr. Torkildsen has served as P.I. on over 20 client-sponsored Dry Eye studies since 2002. In this discussion she takes listeners on a tour of common eye problems faced in primary care, and how clinicians can better prepare themselves to address issues such as Meibobian gland disorders, blepharitis, dry eyes, and conjunctivitis with greater confidence.

Ver tudo (49)

Criado por

ReachMD
Anos de atividade

2014 - 2024
Episódios

49
Classificação

Livre
Site do podcast

Eye on Ocular Health

Ciência

18/04/2018

Eye on Ocular Health

Making the Case for Dual Ang-2/VEGF-A Inhibition: Anatomical Benefits

Making the Case for Dual Ang-2 VEGF-A Inhibition: Durability and Drying

A Vision for Change: Exploring Biosimilars in Retinal Disease Management

Ocular Manifestations of Rheumatological Conditions

FDA-Approved Gene Therapy Reverses Blindness in Children & Adults

Injectable Medication as an Alternative Treatment for Diabetic Eye Disease

Keeping a Clinical Eye on Sickle Cell Retinopathy

Uncommon Details on Common Ocular Conditions

Sobre

Informações

Mais de ReachMD

Eye on Ocular Health

Episódios

Making the Case for Dual Ang-2/VEGF-A Inhibition: Anatomical Benefits

Making the Case for Dual Ang-2 VEGF-A Inhibition: Durability and Drying

A Vision for Change: Exploring Biosimilars in Retinal Disease Management

Ocular Manifestations of Rheumatological Conditions

FDA-Approved Gene Therapy Reverses Blindness in Children & Adults

Injectable Medication as an Alternative Treatment for Diabetic Eye Disease

Keeping a Clinical Eye on Sickle Cell Retinopathy

Uncommon Details on Common Ocular Conditions

Sobre

Informações

Mais de ReachMD